No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: A prospective study

Haemophilia

Volumn 19, Issue 3, 2013, Pages 438-444

  Auerswald, G ^a   Bade, A ^a   Haubold, K ^a   Overberg, D ^a   Masurat, S ^a   Moorthi, C ^a  

^a KLINIKUM BREMEN MITTE   (Germany)

Author keywords

Continuous infusion; Factor concentrate; Haemophilia A; Haemophilia B; Inhibitors; Von Willebrand's disease

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 9; FIX BEHRING; FVIII SDH INTERSERO; HEPARIN; OCTANINE; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLEEDING; BOLUS INJECTION; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEROCONVERSION; SURGICAL TECHNIQUE; VON WILLEBRAND DISEASE; WOUND INFECTION;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHILD, PRESCHOOL; FACTOR IX; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMOPHILIA B; HUMANS; MALE; MIDDLE AGED; ORTHOPEDICS; OTOLARYNGOLOGY; PROSPECTIVE STUDIES; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84876799954     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12075     Document Type: Article

References (37)

1. Guidelines for the Management of Hemophilia. Québec, Canada: World Federation of Hemophilia, 2005.
2. Nichols WL, Hultin MB, James AH et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171-232.
3. Stachnik JM, Gabay MP. Continuous infusion of coagulation factor products. Ann Pharmacother 2002; 36: 882-91.
4. Hathaway WE, Christian MJ, Clarke SL, Hasiba U. Comparison of continuous and intermittent Factor VIII concentrate therapy in hemophilia A. Am J Hematol 1984; 17: 85-8.
5. Mulcahy R, Walsh M, Scully MF. Retrospective audit of a continuous infusion protocol for haemophilia A at a single haemophilia treatment centre. Haemophilia 2005; 11: 208-15.
6. Campbell PJ, Rickard KA. Continuous and intermittent infusion of coagulation factor concentrates in patients undergoing surgery: a single centre Australian experience. Aust N Z J Med 1998; 28: 440-5.
7. Bidlingmaier C, Deml MM, Kurnik K. Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections. Haemophilia 2006; 12: 212-7.
8. Belgaumi AF, Patrick CC, Deitcher SR. Stability and sterility of a recombinant factor VIII concentrate prepared for continuous infusion administration. Am J Hematol 1999; 62: 13-8.
9. Metzner HJ, Watzka B, Muller HG et al. Stability of FactorVIII concentrates - a precondition for continuous infusion. Biomed Prog 1997; 10: 31-4.
10. Lubetsky A, Schulman S, Varon D et al. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease. Thromb Haemost 1999; 81: 229-33.
11. Chowdary P, Dasani H, Jones JA et al. Recombinant factor IX (BeneFix) by adjusted continuous infusion: a study of stability, sterility and clinical experience. Haemophilia 2001; 7: 140-5.
12. von Auer C, Oldenburg J, von Depka M, Escuriola-Ettinghausen C, Kurnik K, Lenk H, et al. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates. Ann N Y Acad Sci 2005; 1051: 498-505.
13. Eckhardt CL, Menke LA, van Ommen CH et al. Intensive peri-operative use of factor VIII and the Arg593->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. J Thromb Haemost 2009; 7: 930-7.
14. Gouw SC, ter Avest PC, van Helden PM, Voorberg J, van den Berg HM. Discordant antibody response in monozygotic twins with severe haemophilia A caused by intensive treatment. Haemophilia 2009; 15: 712-7.
15. Koestenberger M, Leschnik B, Muntean W. More on: mild hemophilia A and inhibitor development. J Thromb Haemost 2004; 2: 676. author reply 7.
16. Carcao M. More on: intensive factor VIII exposure and inhibitor development in mild hemophilia A. J Thromb Haemost 2004; 2: 677.
17. Doughty HA, Coles J, Parmar K, Bullock P, Savidge GF. The successful removal of a bleeding intracranial tumour in a severe haemophiliac using an adjusted dose continuous infusion of monoclonal factor VIII. Blood Coagul Fibrinolysis 1995; 6: 31-4.
18. Koestenberger M, Raith W, Muntean W. High titre inhibitor after continuous factor VIII administration for surgery in a young infant. Haemophilia 2000; 6: 120.
19. van den Berg HM, Roosendaal G, Voorberg J, Mauser-Bunschoten EP. Inhibitor development in a multitransfused patient with severe haemophilia A. Thromb Haemost 1999; 82: 151-2.
20. White B, Cotter M, Byrne M, O'Shea E, Smith OP. High responding factor VIII inhibitors in mild haemophilia - is there a link with recent changes in clinical practice? Haemophilia 2000; 6: 113-5.
21. Yee TT, Lee CA. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor? Thromb Haemost 1999; 81: 852.
22. Batorova A, Martinowitz U. Continuous infusion of coagulation factors: current opinion. Curr Opin Hematol 2006; 13: 308-15.
23. Auerswald G. Continuous infusion of factor VIII after elective surgery in children with hemophilia and von Willebrand Disease. Biomed Prog 1997; 10: 27-30.
24. Frank RD, Kunz D, Wirtz DC. Acquired von Willebrand disease-hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion. Am J Hematol 2002; 70: 64-71.
25. Kuhne T, Imbach P, Marbet GA, Caliezi C, Devay J. Continuous infusion of von Willebrand factor and factor VIII after elective heart surgery in a 12-year-old girl with von Willebrand disease type 3. Pediatr Hematol Oncol 1999; 16: 551-6.
26. Lipkind HS, Kurtis JD, Powrie R, Carpenter MW. Acquired von Willebrand disease: management of labor and delivery with intravenous dexamethasone, continuous factor concentrate, and immunoglobulin infusion. Am J Obstet Gynecol 2005; 192: 2067-70.
27. Martinowitz U, Schulman S, Gitel S, Horozowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol 1992; 82: 729-34.
28. Negrier C, Shapiro A, Berntorp E et al. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients. Thromb Haemost 2008; 100: 217-23.
29. Martinowitz U, Luboshitz J, Bashari D et al. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia. Haemophilia 2009; 15: 676-85.
30. Pruthi RK, Mathew P, Valentino LA, Sumner MJ, Seremetis S, Hoots WK. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial. Thromb Haemost 2007; 98: 726-32.
31. Kenet G, Lubetsky A, Luboshitz J et al. Lower doses of rFVIIa therapy are safe and effective for surgical interventions in patients with severe FXI deficiency and inhibitors. Haemophilia 2009; 15: 1065-73.
32. Smith MP, Rice KM, Bromidge ES et al. Continuous infusion therapy with very high purity von Willebrand factor concentrate in patients with severe von Willebrand disease. Blood Coagul Fibrinolysis 1997; 8: 6-12.
33. Gerling V, Lahpor JR, Buhre W. Peri-operative management of an adult patient with type 2N von Willebrand's disease scheduled for coronary artery bypass graft. Anaesthesia 2007; 62: 405-8.
34. Lubetsky A, Martinowitz U, Luboshitz J et al. Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. Haemophilia 2002; 8: 622-8.
35. Auerswald G, Eberspacher B, Engl W et al. Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII/von Willebrand factor concentrate (Immunate). Semin Thromb Hemost 2002; 28: 203-14.
36. Grossmann RE, Geisen U, Schwender S, Keller F. Continuous infusion of recombinant factor VIIa (NovoSeven) in the treatment of a patient with type III von Willebrand's disease and alloantibodies against von Willebrand factor. Thromb Haemost 2000; 83: 633-4.
37. Franchini M, Gandini G, Giuffrida A, De Gironcoli M, Federici AB. Treatment for patients with type 3 von Willebrand disease and alloantibodies: a case report. Haemophilia 2008; 14: 645-6.